A Phase 2, Open-Label, Multicenter Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Patients With Relapsed and/or Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Takeda
- 25 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 29 Nov 2016 Status changed from not yet recruiting to recruiting.
- 29 Sep 2016 New trial record